EPS for Onconova Therapeutics, Inc. (ONTX) Expected At $-0.08

July 14, 2018 - By Darrel Chase

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Logo

Analysts expect Onconova Therapeutics, Inc. (NASDAQ:ONTX) to report $-0.08 EPS on August, 13.They anticipate $0.21 EPS change or 72.41 % from last quarter’s $-0.29 EPS. After having $-0.34 EPS previously, Onconova Therapeutics, Inc.’s analysts see -76.47 % EPS growth. The stock 1.07% or $0 during the last trading session, reaching $0.45. It is down 81.06% since July 14, 2017 and is downtrending. It has underperformed by 93.63% the S&P500.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Coverage

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Onconova Therapeutics had 8 analyst reports since January 17, 2018 according to SRatingsIntel. H.C. Wainwright maintained Onconova Therapeutics, Inc. (NASDAQ:ONTX) on Tuesday, May 15 with “Buy” rating. The stock has “Hold” rating by Maxim Group on Wednesday, January 31. The rating was maintained by H.C. Wainwright on Thursday, January 18 with “Buy”. The firm earned “Buy” rating on Wednesday, May 2 by Maxim Group. The firm has “Hold” rating by Maxim Group given on Wednesday, January 17. The firm has “Buy” rating by H.C. Wainwright given on Thursday, March 1. H.C. Wainwright maintained the shares of ONTX in report on Monday, March 26 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Friday, March 9.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $35.22 million. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

Another recent and important Onconova Therapeutics, Inc. (NASDAQ:ONTX) news was published by Globenewswire.com which published an article titled: “Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, MD” on June 21, 2018.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.